IAM: Pipeline progress and $455M pro forma cash position support planned 2027 milestones

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Q3 collaboration revenue rose to $11.4M from $4.7M, while net loss widened to $38.5M, including a $10.4M noncash convertible-note charge. October IPO proceeds and AbbVie payments lifted pro forma cash to $455M; 2027 pipeline milestones are planned.

Original document: Iambic Therapeutics, Inc. [IAM] SEC 8-K Current Report — Nov. 16 2026

Disclaimer
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Source: Quartr The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.